molecules of the month


CNS-pen. GABAA-_5 neg. allo. mod. (NAM)

Ph. II for Down syndrome (240 mg BID)

from 56k cmpd competition binding HTS

Sci. Rep., Apr. 8, 2021

Roche Innovation Center, Basel, CH

1 min read

The Roche GABAA-α5 selective negative allosteric modulator (NAM), basmisanil, is a Ph. II candidate for intellectual disability in Down syndrome. GABAA receptors assemble as pentamers of subunits, and non- subunit selective compounds have anxiogenic or convulsive side effects. Basimasil is the only safe and selective GABAA-α5 inhibitor that has entered clinical development. It is highly selective for the GABAA-α5 receptor subtype and is >90x selective against -α1, -α2, and -α3 subunit-containing receptors, and accordingly demonstrated good tolerability in healthy volunteers at maximum target occupancy, confirmed with a [11C]-radiolabeled PET tracer. The team reports human PET and EEG data in this paper, providing evidence for functional target engagement in the human brain for this well-tolerated compound.

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: